King extends Alpharma tender offer; Abbott announces $5B stock buyback;

> King Pharmaceuticals extended its $37-a-share tender offer for Alpharma through Nov. 21; by Friday, about 45 percent of the company's outstanding shares had been tendered. King release

> Abbott Laboratories will buy back up to $5 billion in stock under a newly announced share buyback program; the company had 1.54 billion shares outstanding at a closing price of $49.45 on Friday. Abbott release

> The family of a U.S. soldier blames the malaria drug Lariam for his suicide, and an Army psychiatrist suggests the medication was a factor in the man's death. Report

> A group of CEOs is hoping to save companies time and money by improving the legal contracts required to initiate cancer trials. Report

> The Indian government plans to open generic drug stores in eleven states in collaboration with the pharmaceutical industry, state governments and non-governmental organizations, aiming to make drugs available at cheaper prices on a mass scale. Report

> Jerini and Shire have reviewed Jerini's assets and have elected to divest Jerini Ophthalmic, JPT Peptide Technologies and Jerini's pre-clinical projects. Jerini report

> A subsidiary of German drugmaker Schwarz Pharma Manufacturing will upgrade its manufacturing and distribution facility in Seymour, Ind., adding 150 jobs over the next three years. Report

> India's Wockhardt announced that it has in-licensed dermatology and dental programs from he UK-based company Sinclair Pharma. Wockhardt report

> The FDA informed Takeda that it will miss the review deadline for alogliptin, a type 2 diabetes treatment. The NDA was supposed to be reviewed by October 7, 2008, but will be delayed due to "internal resource constraints" at the agency. FDA report

> Wyeth is putting the finishing touches on its regulatory application for Prevnar-13, the latest generation in a series of jabs that defend against pneumococcal disease. The applications will be filed in the U.S. and Europe early next year. Wyeth report

> More evidence that pre-priming a population with avian flu jabs would help mount a rapid response to any outbreak in the future. British researchers tested the approach on a group of patients who had been vaccinated between 1999 and 2001. After being given a new avian flu vax, 80 percent of them demonstrated an immune response after just one week. Vaccines report

And Finally... Attention Chardonnay drinkers: White wines may offer heart benefits similar to reds. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.